The hypothalamic pituitary axis in the fetus and newborn

Area of Science:

• Neonatal Medicine
• Pediatric Endocrinology
• Fetal Development

Background:

• Glucocorticoid receptor activation is crucial for fetal lung maturation, aiding extra-uterine adaptation.
• Antenatal glucocorticoids (betamethasone, dexamethasone) reduce respiratory distress in premature infants.
• Postnatal dexamethasone offers short-term benefits for chronic lung disease but survival benefits are unclear.

Purpose of the Study:

• To evaluate the efficacy and safety of traditional glucocorticoid therapy in premature infants.
• To explore potential derangements in the fetal hypothalamic/pituitary/adrenal axis due to dexamethasone.
• To consider alternative glucocorticoid therapies for premature infants with persistent fetal patterns.

Main Methods:

• Review of existing data on antenatal and postnatal glucocorticoid treatments.
• Analysis of the impact of dexamethasone on the developing fetal hypothalamic/pituitary/adrenal axis.
• Consideration of alternative glucocorticoid regimens and their potential benefits.

Main Results:

• Surfactant therapy has reduced the comparative advantage of antenatal glucocorticoids.
• Postnatal dexamethasone's impact on survival remains uncertain.
• Glucocorticoid treatment is associated with adverse effects including reduced growth, adrenal suppression, and increased infection risk.

Conclusions:

• Dexamethasone therapy may disrupt the precise fetal hypothalamic/pituitary/adrenal axis development.
• Persistent fetal patterns in premature infants may indicate adrenal insufficiency.
• Less potent glucocorticoids at stress replacement doses could be a safer alternative, avoiding side effects.